Editorial: Treatment of childhood leukemia.
D000208:Acute Disease; D000367:Age Factors; D002490:Central Nervous System / Q000528:radiation effects; D002493:Central Nervous System Diseases / Q000517:prevention & control / Q000532:radiotherapy; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D007278:Injections, Spinal; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011830:Radiation Effects; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate